Business News MatrixInsights & Trends in Business, Tech, and Lifestyle
ArkBio Announces FDA Clearance to Initiate Phase II Trial of AK0406 for Influenza Prevention

news

ArkBio Announces FDA Clearance to Initiate Phase II Trial of AK0406 for Influenza Prevention

By Sai Krishna

SHANGHAI , Oct. 13, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the U.S. Food and Drug Administration (FDA) has granted its investigational new drug (IND) application for AK0406, a long-acting antiviral drug-Fc conjugate (AFC), enabling the company to initiate a phase II clinical trial for influenza prevention in general population in the United States. Addressing...